Table 1.

Clinical characteristics of MCL patients

Patient ID	Diagnosis	Treatment	Immunophenotype
1 (DA)	MCL	Treatment naive	CD5+CD19+ (86.1%+)
2 (U-21-0319)	MCL	Treatment naive	CD5+CD19+ (85.5%+)
3 (U-21-2484)	MCL	R/R status post chemotherapy including ASCT, targeted therapies including ibrutinib and venetoclax, and progressed after commercial CD19 CAR-Ts	CD5+CD19+ (95.2%+)
4 (U-18-0530)	MCL	Treatment naive	CD5+CD19+ (85.4%+)
5 (U-19-1409)	MCL	R/R status post chemotherapy and ibrutinib	CD5−CD19+ (73.7%+)